UroShield Cited as Effective in Preventing CAUTIs and Blockages and Having a Major Impact on Quality of Life

NanoVibronix, Inc., (NASDAQ: NAOV), a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced that its UroShield is featured in Issue 103 of Your Bladder Health Magazine in an article titled ‘UroShield Prevention is better than cure.’ The article highlights the effectiveness of using UroShield in the prevention of catheter associated urinary tract infections (CAUTIs). The article also includes testimonials that detail the positive impact that UroShield has had on the lives of patients.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231206453100/en/

(Graphic: Business Wire)

Brian Murphy, Chief Executive Officer of NanoVibronix, Inc., said, “This article reinforces our efforts to raise market and clinician awareness, a key driver to accelerating adoption and increasing sales. It highlights the effectiveness of UroShield in preventing episodes of CAUTI and blockages, which in turn, reduces the need for antibiotics and prolonged hospital stays, thereby lowering healthcare costs. Just as important, the patient testimonials and endorsements provide compelling evidence of the positive impact UroShield can have on a patient’s quality of life.”

From the article:

‘Currently, even after many years, the most effective treatments are frequent catheter changes for catheter blockages, and possibly antibiotics for CAUTIs and in more serious cases hospital inpatient episodes, with IV antibiotics to resolve.

Not only does this all have a major impact on people’s quality of life, and the already mentioned strain on NHS resources and finances, but the increased use of antibiotics is something which is of concern globally.

Thankfully UroShield addresses and solves all these serious concerns and has some additional benefits to users in reducing pain associated with catheter use, and a reduction in bladder spasms which some people suffer from.’

About NanoVibronix, Inc.

NanoVibronix, Inc. (NASDAQ: NAOV) is a medical device company headquartered in Elmsford, New York, with research and development in Nesher, Israel, focused on developing medical devices utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The Company’s primary products include PainShield® and UroShield®, which are portable devices suitable for administration at home without assistance of medical professionals. Additional information about NanoVibronix is available at: www.nanovibronix.com

Forward-looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with: (i) market acceptance of our existing and new products or lengthy product delays in key markets; (ii) negative or unreliable clinical trial results; (iii) inability to secure regulatory approvals for the sale of our products; (iv) intense competition in the medical device industry from much larger, multinational companies; (v) product liability claims; (vi) product malfunctions; (vii) our limited manufacturing capabilities and reliance on subcontractor assistance; (viii) insufficient or inadequate reimbursements by governmental and/or other third party payers for our products; (ix) our ability to successfully obtain and maintain intellectual property protection covering our products; (x) legislative or regulatory reform impacting the healthcare system in the U.S. or in foreign jurisdictions; (xi) our reliance on single suppliers for certain product components, (xii) the need to raise additional capital to meet our future business requirements and obligations, given the fact that such capital may not be available, or may be costly, dilutive or difficult to obtain; (xiii) our conducting business in foreign jurisdictions exposing us to additional challenges, such as foreign currency exchange rate fluctuations, logistical and communications challenges, the burden and cost of compliance with foreign laws, and political and/or economic instabilities in specific jurisdictions; and (xiv) market and other conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at: http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231206453100/en/